SCHEMBL26212915

SCHEMBL26212915

O=S(=O)(NCCCl)c1ccc(C2CCCCC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
ALDH1A1 P00352 4/20 0.52
MAPT P10636 3/20 0.52
TP53 P04637 1/20 0.52
ATM Q13315 1/20 0.52
HTT P42858 4/20 0.51
XBP1 P17861 1/20 0.51
KDM4E B2RXH2 2/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PTGES2 Q9H7Z7 1/20 0.48
TSHR P16473 1/20 0.48
HPGD P15428 1/20 0.47
KMT2A Q03164 3/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
BRD4 O60885 1/20 0.44
TRIM24 O15164 1/20 0.43
APOBEC3A P31941 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31674606 0.85 ALDH1A1 (0.53) LMNASMN1; SMN2ALDH1A1MAPTTP53
SCHEMBL23045633 0.81 LMNA (0.52) LMNASMN1; SMN2ALDH1A1MAPTTP53
SCHEMBL23045683 0.80 KMT2A (0.65) LMNASMN1; SMN2ALDH1A1MAPTTP53
SCHEMBL19381795 0.79 LMNA (0.59) LMNASMN1; SMN2ALDH1A1MAPTTP53
SCHEMBL23052430 0.77 MAPK1 (0.63) LMNASMN1; SMN2ALDH1A1TP53ATM
SCHEMBL23867529 0.76 PKM (0.61) SMN1; SMN2ALDH1A1MAPK1HPGDKMT2A
SCHEMBL23052427 0.76 TDP1 (0.67) SMN1; SMN2ALDH1A1TP53HTTTSHR
SCHEMBL26212992 0.75 GBA1 (0.46) LMNASMN1; SMN2ALDH1A1HPGDKMT2A
SCHEMBL23118350 0.74 GAA (0.66) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL11705004 0.74 LMNA (0.48) LMNASMN1; SMN2ALDH1A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115843271-B Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2024-08-13 CN disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 LMNA 3774/4885SMN1; SMN2 4836/4885ALDH1A1 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.